Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of ...

Please provide your email address to receive an email when new articles are posted on . A phase 1/2 trial will assess safety, tolerability and preliminary efficacy for VG801. The FDA also selected ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

SpliceBio CEO and co-founder Miquel Vila-Perelló said: “The FDA IND clearance of SB-007 is a significant achievement for SpliceBio and Stargardt disease patients. As the first-ever IND for a ...

Caitlin and Caoimhe Mynes stole the hearts of viewers when they had the craic with Ryan Tubridy making lava lamps and glitter ...

Splicebio S.L. has gained IND clearance from the FDA for its lead program SB-007, a protein splicing gene therapy to address the root genetic cause of Stargardt disease. The company plans to initiate ...

Alkeus’ presentation, which will include new data from the company’s TEASE-3 study of gildeuretinol in early-stage patients with Stargardt disease, will be Tuesday, January 14, at 4:30 p.m. PST at The ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...